Zdrowie i gospodarka · 09/03/2016
FDA Announces Draft Guidance for Evaluating Respiratory Symptoms in COPD
The FDA has released a draft guidance for industry on evaluating respiratory symptoms in chronic obstructive pulmonary disease (COPD) using a patient-reported outcome instrument, allowing for exploratory use in drug development and regulatory review.
Source: Federal Register — Food and Drug AdministrationOpen original release →